Myriad Genetics (MYGN) Proxy filing summary

Voting matters and shareholder proposals

• Election of three Class III Directors to serve until the 2029 Annual Meeting: Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D., with the board recommending a vote for each nominee.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.

• Advisory approval of named executive officer compensation as disclosed in the proxy statement.

• Approval of an amendment to the Amended and Restated 2012 Employee Stock Purchase Plan.

• Approval of the proposed 2026 Employee, Director and Consultant Equity Incentive Plan.

Board of directors and corporate governance

• Board recommends all director nominees and proposals for shareholder approval.

• Proxies are authorized to vote on any other business that may properly come before the meeting.

Audit committee and external auditor matters

• Proposal to ratify Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year.